CN107849117B - 用于治疗纤维化的内皮抑素片段和变体 - Google Patents

用于治疗纤维化的内皮抑素片段和变体 Download PDF

Info

Publication number
CN107849117B
CN107849117B CN201680044858.5A CN201680044858A CN107849117B CN 107849117 B CN107849117 B CN 107849117B CN 201680044858 A CN201680044858 A CN 201680044858A CN 107849117 B CN107849117 B CN 107849117B
Authority
CN
China
Prior art keywords
endostatin
plant
seq
fibrosis
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680044858.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN107849117A (zh
Inventor
C·费加利-博斯特威克
T·E·瑞安
H·S·帕吉特
M·麦吉
R·B·霍尔茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MUSC Foundation for Research and Development
Fraunhofer USA Inc
Novici Biotech LLC
Original Assignee
MUSC Foundation for Research and Development
Fraunhofer USA Inc
Novici Biotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MUSC Foundation for Research and Development, Fraunhofer USA Inc, Novici Biotech LLC filed Critical MUSC Foundation for Research and Development
Priority to CN202210968572.3A priority Critical patent/CN115925878A/zh
Publication of CN107849117A publication Critical patent/CN107849117A/zh
Application granted granted Critical
Publication of CN107849117B publication Critical patent/CN107849117B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201680044858.5A 2015-06-05 2016-06-03 用于治疗纤维化的内皮抑素片段和变体 Active CN107849117B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210968572.3A CN115925878A (zh) 2015-06-05 2016-06-03 用于治疗纤维化的内皮抑素片段和变体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562171889P 2015-06-05 2015-06-05
US62/171,889 2015-06-05
US201562257607P 2015-11-19 2015-11-19
US62/257,607 2015-11-19
PCT/US2016/035858 WO2016197018A1 (en) 2015-06-05 2016-06-03 Endostatin fragments and variants for use in treating fibrosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210968572.3A Division CN115925878A (zh) 2015-06-05 2016-06-03 用于治疗纤维化的内皮抑素片段和变体

Publications (2)

Publication Number Publication Date
CN107849117A CN107849117A (zh) 2018-03-27
CN107849117B true CN107849117B (zh) 2022-08-26

Family

ID=56236074

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680044858.5A Active CN107849117B (zh) 2015-06-05 2016-06-03 用于治疗纤维化的内皮抑素片段和变体
CN202210968572.3A Pending CN115925878A (zh) 2015-06-05 2016-06-03 用于治疗纤维化的内皮抑素片段和变体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210968572.3A Pending CN115925878A (zh) 2015-06-05 2016-06-03 用于治疗纤维化的内皮抑素片段和变体

Country Status (10)

Country Link
US (2) US10844392B2 (https=)
EP (1) EP3303383A1 (https=)
JP (2) JP6952685B2 (https=)
KR (1) KR20180033499A (https=)
CN (2) CN107849117B (https=)
AU (2) AU2016270428B2 (https=)
BR (1) BR112017026209A2 (https=)
CA (1) CA2988299C (https=)
WO (1) WO2016197018A1 (https=)
ZA (1) ZA201708223B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3303383A1 (en) * 2015-06-05 2018-04-11 iBio, Inc. Endostatin fragments and variants for use in treating fibrosis
NZ774126A (en) * 2018-09-14 2023-05-26 Akso Biopharmaceutical Inc Spd-1 variant - fc fusion proteins
US20210008173A1 (en) * 2019-07-10 2021-01-14 Musc Foundation For Research Development Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury
EP3996694A1 (en) * 2019-07-31 2022-05-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Peptides as inhibitors of fibrotic matrix accumulation
JP7493945B2 (ja) * 2020-01-28 2024-06-03 ポーラ化成工業株式会社 培養組織の観察方法、培養方法、評価方法及び培養器具
WO2022006601A1 (en) * 2020-07-02 2022-01-06 Northwestern University Human recombinant ace2-fc mutants that decouple anti-sars-cov-2 activity from cardiovascular effects
AU2021386254A1 (en) * 2020-11-30 2023-06-29 Blaze Bioscience, Inc. Compositions and methods for selective depletion of target molecules
WO2023039399A2 (en) * 2021-09-07 2023-03-16 Musc Foundation For Research Development Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050311A1 (en) * 2009-10-22 2011-04-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Use of endostatin peptides for the treatment of fibrosis
CN103890003A (zh) * 2011-07-19 2014-06-25 特拉索斯创新公司 抗纤维化肽及其在用于治疗以纤维化为特征的疾病和病症的方法中的用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US750375A (en) 1904-01-26 Potato-digger
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5093258A (en) 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
JP3039802B2 (ja) 1989-07-06 2000-05-08 ザ リージェンツ オブザ ユニバーシティ オブ カリフォルニア 繊維芽細胞成長因子のための受容体
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5756671A (en) 1994-06-02 1998-05-26 Mitotix, Inc. CDC37 cell-cycle regulatory protein, and uses related thereto
US6080560A (en) * 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6165460A (en) 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
DE19535939A1 (de) 1995-09-27 1997-04-03 Agfa Gevaert Ag Fotografisches Material
ATE319840T1 (de) 1997-12-08 2006-03-15 Beth Israel Hospital Verfahren zur herstellung von anti-angiogene proteine; endostatin, angiostatin oder restin, mit einem expressions-system für hefe pichia
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
AU4414099A (en) * 1998-06-03 1999-12-20 Children's Medical Center Corporation Protein oligomer compositions comprising endostatin protein and methods of usingthe same
AU4859399A (en) 1998-07-02 2000-01-24 President And Fellows Of Harvard College Compositions and methods for treating papillomavirus-infected cells
EP1147178A1 (en) 1999-02-05 2001-10-24 Thomas Jefferson University Production of biomedical peptides and proteins in plants using transcomplementation systems
US6656728B1 (en) 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
EP1594956A4 (en) 2003-02-03 2007-08-01 Fraunhofer Usa Inc SYSTEM FOR EXPRESSION OF GENES IN PLANTS
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
US20110038865A1 (en) * 2007-06-26 2011-02-17 University Of Miami Antibody- endostatin fusion protein and its variants
EP3303383A1 (en) 2015-06-05 2018-04-11 iBio, Inc. Endostatin fragments and variants for use in treating fibrosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050311A1 (en) * 2009-10-22 2011-04-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Use of endostatin peptides for the treatment of fibrosis
CN103890003A (zh) * 2011-07-19 2014-06-25 特拉索斯创新公司 抗纤维化肽及其在用于治疗以纤维化为特征的疾病和病症的方法中的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A Peptide Derived from Endostatin Ameliorates Organ Fibrosis;Yukie Yamaguchi等;《Sci Transl Med》;20130330;第4卷(第136期);全文 *
The anti-fibrotic effect of betulinic acid is mediated through the inhibition of NF-κB nuclear protein translocation;Ying Wan等;《Chemico-biological interactions》;20120121;第195卷(第3期);全文 *

Also Published As

Publication number Publication date
JP2018524019A (ja) 2018-08-30
CN107849117A (zh) 2018-03-27
WO2016197018A9 (en) 2017-01-19
KR20180033499A (ko) 2018-04-03
US10844392B2 (en) 2020-11-24
ZA201708223B (en) 2018-11-28
CN115925878A (zh) 2023-04-07
US20180179263A1 (en) 2018-06-28
BR112017026209A2 (pt) 2018-11-27
AU2016270428B2 (en) 2020-11-26
WO2016197018A8 (en) 2017-07-13
US11912755B2 (en) 2024-02-27
JP7404320B2 (ja) 2023-12-25
EP3303383A1 (en) 2018-04-11
CA2988299C (en) 2023-10-31
US20210108221A1 (en) 2021-04-15
WO2016197018A1 (en) 2016-12-08
AU2021200765A1 (en) 2021-03-04
JP2022002527A (ja) 2022-01-11
JP6952685B2 (ja) 2021-10-20
CA2988299A1 (en) 2016-12-08
AU2016270428A1 (en) 2018-01-25
AU2021200765B2 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
CN107849117B (zh) 用于治疗纤维化的内皮抑素片段和变体
US10709769B2 (en) Use of endostatin peptides for the treatment of fibrosis
KR20140128971A (ko) 세포-투과성 펩티드
CN113024643B (zh) 一种人工拟肽及其制备方法和应用
CN114846020B (zh) 逆向-反转肽
EP2797617B1 (en) Anti-tumor adjuvant therapy
KR101625502B1 (ko) 대장상피세포의 성장을 촉진하는 신규 스콜로펜드라신-4 펩타이드 및 그의 조성물
WO2022111713A9 (zh) 一种含有二硫键且具有抑制丝氨酸蛋白酶活性的多肽、其衍生的杂交肽及其应用
EP2963053A1 (en) Peptides for promoting angiogenesis and an use thereof
WO2022109679A1 (en) Peptides and uses thereof in modulation of amyloid-beta protein degrading proteases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: C - feghali Bostwick

Inventor after: T E Ruian

Inventor after: H - S - Paget

Inventor after: M. Maggie

Inventor after: Holtz R. Barry

Inventor before: C - feghali Bostwick

Inventor before: T E Ruian

Inventor before: H - S - Paget

Inventor before: M. Maggie

CB03 Change of inventor or designer information
GR01 Patent grant
GR01 Patent grant